Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disorder rather than an isolated liver condition. Hypertension is one of the most common and clinically important comorbidities in patients with MASLD, contributing to cardiovascular, renal, and potentially liver-related disease burden. This chapter summarizes recent advances in the pathophysiological and clinical links between hypertension and MASLD. Shared mechanisms include insulin resistance, visceral adiposity, adipose tissue dysfunction, renin-angiotensin-aldosterone system activation, sympathetic nervous system activation, oxidative stress, chronic inflammation, endothelial dysfunction, and gut-liver axis dysregulation. These pathways may jointly promote hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH) progression, liver fibrosis, blood pressure elevation, vascular injury, and cardiovascular risk. Clinical evidence from studies using earlier nonalcoholic fatty liver disease (NAFLD) definitions, together with emerging MASLD-based evidence, suggests a close relationship between hypertension and MASLD, with some studies also supporting a potential bidirectional association, although causality remains difficult to establish. Hypertension has also been associated with liver stiffness progression, histological fibrosis progression, and adverse clinical outcomes in MASLD. Risk stratification should therefore integrate liver, cardiovascular, renal, and metabolic assessment, including non-invasive fibrosis evaluation and global cardiovascular risk management. Lifestyle intervention, metabolic risk control, and appropriate blood pressure management remain central to clinical care. Future research should clarify causal pathways, define optimal screening strategies, and determine whether antihypertensive treatment alone can improve hepatic steatosis, MASH, or liver fibrosis beyond its established cardiovascular and renal benefits.